v3.26.3
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended 30 Months Ended 36 Months Ended
Sep. 27, 2026
Sep. 28, 2025
Sep. 27, 2026
Sep. 28, 2025
Sep. 27, 2026
Sep. 27, 2026
Restructuring charges/(credits):            
Employee terminations $ 702 $ 124 $ 1,071 $ 360    
Asset impairments 30 111 112 328    
Exit costs 21 2 38 96    
Restructuring charges/(credits) [1] 753 237 1,221 784    
Transaction costs 2 0 2 0    
Integration costs and other [2] 35 49 124 162    
Restructuring charges and certain acquisition-related costs 791 286 1,347 945    
Inventory write-offs––recorded in Cost of sales 6 33 52 33    
Additional depreciation––asset restructuring recorded in condensed consolidated statements of operations [3] 14 4 28 11    
Implementation costs [4] 131 105 364 234    
Total costs associated with acquisitions and cost-reduction/productivity initiatives 940 423 1,788 1,150    
Biopharma [Member]            
Restructuring charges/(credits):            
Restructuring charges/(credits) 461 240 882 451    
Biopharma [Member] | Manufacturing Optimization Program [Member]            
Restructuring charges/(credits):            
Restructuring charges/(credits) 65 117 14 (295) $ 889  
Biopharma [Member] | Realigning Our Cost Base Program [Member]            
Restructuring charges/(credits):            
Restructuring charges/(credits) 385 107 849 669   $ 3,700
Income Statement Location [Axis]: us-gaap:CostOfGoodsAndServicesSold            
Restructuring charges/(credits):            
Additional depreciation––asset restructuring recorded in condensed consolidated statements of operations [3] 14 3 27 10    
Implementation costs [4] 21 26 61 72    
Income Statement Location [Axis]: us-gaap:OtherNonoperatingIncomeExpense            
Restructuring charges/(credits):            
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net (1) (6) (3) (74)    
Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost            
Restructuring charges/(credits):            
Additional depreciation––asset restructuring recorded in condensed consolidated statements of operations [3] 0 1 0 1    
Implementation costs [4] 60 53 162 116    
Income Statement Location [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense            
Restructuring charges/(credits):            
Implementation costs [4] $ 50 $ 26 $ 142 $ 46    
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $461 million for the three months ended September 27, 2026 (including charges of $385 million for our Realigning our Cost Base Program and charges of $65 million for our Manufacturing Optimization Program), (ii) charges of $882 million for the nine months ended September 27, 2026 (including charges of $849 million for our Realigning our Cost Base Program and charges of $14 million for our Manufacturing Optimization Program), (iii) charges of $240 million for the three months ended September 28, 2025 (including charges of $117 million for our Manufacturing Optimization Program and charges of $107 million for our Realigning our Cost Base Program) and (iv) charges of $451 million for the nine months ended September 28, 2025 (including charges of $669 million for our Realigning our Cost Base Program and credits of $295 million for our Manufacturing Optimization Program). For the nine months ended September 28, 2025, Employee terminations included revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.
[2] Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
[3] Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[4] Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.